Anti-kir3d antibodies
US-2016046713-A1 · Feb 18, 2016 · US
Humanized antibodies with increased stability
US10280222B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10280222-B2 |
| Application number | US-201515125216-A |
| Country | US |
| Kind code | B2 |
| Filing date | Mar 12, 2015 |
| Priority date | Mar 14, 2014 |
| Publication date | May 7, 2019 |
| Grant date | May 7, 2019 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention provides antibodies having improved stability. Included are antibodies that are capable of binding to KIR3DL2 polypeptides. The antibodies are suitable for the treatment of disorders characterized by KIR3DL2-expressing cells, particularly CD4+T cells, including malignancies such as Mycosis Fungoides and Sezary Syndrome, and KIR3DL2-expressing autoimmune disorders.
First claim
Opening claim text (preview).
The invention claimed is: 1. An antibody or antibody fragment that binds to a KIR3DL2 polypeptide, wherein the antibody or antibody fragment comprise a VH and VL region comprising the amino acid sequence of SEQ ID NOs: 31 and 25, respectively. 2. A pharmaceutical composition comprising an antibody or antibody fragment of claim 1 , and a pharmaceutically acceptable carrier. 3. The composition of claim 2 comprising: (a) about 0.05 mg/mL to about 10 mg/mL of said antibody; (b) buffer system; and (c) isotonic agent, at a pH of between 6.5 and 8. 4. A method for the treatment of a disease in a patient in need thereof, the method comprising administering to said patient an effective amount of an antibody of claim 1 , the disease being selected from a T cell lymphoma, Mycosis fungoides, and Sezary Syndrome. 5. The method of claim 4 , wherein said disease is a peripheral T cell lymphoma. 6. The method of claim 4 , wherein said disease is Mycosis fungoides. 7. The method of claim 4 , wherein said disease is Sezary Syndrome.
Assignees
Inventors
Classifications
Immunosuppressants, e.g. drugs for graft rejection · CPC title
Drugs for immunological or allergic disorders · CPC title
specific for leukemia · CPC title
Antineoplastic agents · CPC title
Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10280222B2 cover?
- The present invention provides antibodies having improved stability. Included are antibodies that are capable of binding to KIR3DL2 polypeptides. The antibodies are suitable for the treatment of disorders characterized by KIR3DL2-expressing cells, particularly CD4+T cells, including malignancies such as Mycosis Fungoides and Sezary Syndrome, and KIR3DL2-expressing autoimmune disorders.
- Who is the assignee on this patent?
- Innate Pharma
- What technology area does this patent fall under?
- Primary CPC classification C07K16/2803. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue May 07 2019 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 4 related publications on this page (citations in our corpus or others sharing the same primary CPC).